We are proud to announce that ForteBio, the industry standard for label-free analysis across biologics development and manufacturing, is now part of the Sartorius Group!
Sartorius, a global partner in the international life science research and biopharmaceutical industries, acquired this innovative Life Science platform business as a strategic expansion of the Sartorius portfolio and a complement to our existing innovative analysis portfolios.
ForteBio’s Bio-Layer Interferometry (BLI) systems complement Sartorius’s overall offering to our customers engaged in drug discovery/development and biomanufacturing. BLI is a label-free, optical analytical technology providing real-time analysis of biomolecular interactions (protein quantification and characterization of protein-biomolecular interactions, etc.) in micro-volume sample sizes, providing information on binding affinity, binding kinetics, and concentration. This technology is an indispensable tool for removing bottlenecks and increasing throughput during antibody screening and cell line development efforts. Consolidating allows us to leverage a broader range of products and an increased knowledge base to continue our quest to provide innovative technologies and solutions to life science researchers.
ForteBio Octet systems enable real-time, label-free analysis for determination of affinity, kinetics, and antibody/protein concentration. Assays are performed using biosensors, reagent and assay kits in 96- and 384-well microplates making it a significantly easier and faster technique than other comparative label-free technologies.
- Use the fluidics-free Octet systems with 96- and/or 384-well sample plates and the ready-to-use biosensors for flexibility in sample types; from large biologics to small molecules, purified or in crude form.
- Perform your quantitation, epitiope binning or kinetics experiments with unmatched speed. Quantitate up to 96-samples of an IgG sample in two minutes on the Octet HTX system.
- Rapidly develop and validate Octet methods for lot release ligand binding, quantitation, and impurity assays.
“With the Octet platform of ForteBio, we will add a broadly accepted and differentiated technology for advancing and simplifying drug discovery to our lab division’s portfolio. We look very much forward to welcoming the new team to Sartorius and to jointly combine our capabilities for the benefit of our biopharma and life science customers.”
— Dr. Joachim Kreuzburg, CEO of Sartorius